Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C25H31FO8 |
Molecular Weight | 478.5072 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12C[C@@H](OC(C)=O)[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]3(F)[C@@]2([H])CCC4=CC(=O)C=C[C@]34C
InChI
InChIKey=XGMPVBXKDAHORN-RBWIMXSLSA-N
InChI=1S/C25H31FO8/c1-13(27)33-12-20(31)25(32)21(34-14(2)28)10-18-17-6-5-15-9-16(29)7-8-22(15,3)24(17,26)19(30)11-23(18,25)4/h7-9,17-19,21,30,32H,5-6,10-12H2,1-4H3/t17-,18-,19-,21+,22-,23-,24-,25+/m0/s1
Molecular Formula | C25H31FO8 |
Molecular Weight | 478.5072 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/19744340
http://www.drugbank.ca/drugs/DB00620
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/19744340
http://www.drugbank.ca/drugs/DB00620
Triamcinolone is a long-acting synthetic corticosteroid primarily used for their anti-inflammatory effects in disorders of many organ systems. Triamcinolone diacetate injectable suspension is indicated for intramuscular use as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiform (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency, congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate ant tuberculous chemotherapy. For palliative management of leukemia’s and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate ant tuberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. As adjunctive therapy for short-term administration in acute gouty arthritis; acute rheumatic carditis. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins that, through inhibition of arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Firstly, however, these glucocorticoids bind to the glucocorticoid receptors, which translocate into the nucleus, bind DNA (GRE), and change genetic expression both positively and negatively. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2034 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19744340 |
1.5 nM [IC50] | ||
Target ID: P04150 Gene ID: 2908.0 Gene Symbol: NR3C1 Target Organism: Homo sapiens (Human) Sources: https://www.genome.jp/dbget-bin/www_bget?dr:D00984 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | ARISTOCORT Approved Useis indicated for intramuscular use as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.Gastrointestinal Disease: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Launch Date1957 |
|||
Palliative | ARISTOCORT Approved Useis indicated for intramuscular use as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.Gastrointestinal Disease: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Launch Date1957 |
|||
Palliative | ARISTOCORT Approved Useis indicated for intramuscular use as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.Gastrointestinal Disease: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Launch Date1957 |
|||
Palliative | ARISTOCORT Approved Useis indicated for intramuscular use as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.Gastrointestinal Disease: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Launch Date1957 |
|||
Palliative | ARISTOCORT Approved Useis indicated for intramuscular use as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.Gastrointestinal Disease: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Launch Date1957 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7202 ng/mL |
4 mg single, ocular dose: 4 mg route of administration: Ocular experiment type: SINGLE co-administered: |
TRIAMCINOLONE unknown | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1911 ng × h/mL |
4 mg single, ocular dose: 4 mg route of administration: Ocular experiment type: SINGLE co-administered: |
TRIAMCINOLONE unknown | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
18.7 day |
4 mg single, ocular dose: 4 mg route of administration: Ocular experiment type: SINGLE co-administered: |
TRIAMCINOLONE unknown | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
120 mg 1 times / day multiple, intramuscular Higher than recommended Dose: 120 mg, 1 times / day Route: intramuscular Route: multiple Dose: 120 mg, 1 times / day Sources: Page: p.588 |
unhealthy, 28-57 n = 12 Health Status: unhealthy Condition: Asthma Age Group: 28-57 Sex: M+F Population Size: 12 Sources: Page: p.588 |
|
360 mg single, intramuscular Highest studied dose Dose: 360 mg Route: intramuscular Route: single Dose: 360 mg Sources: Page: p.1465 |
unhealthy, 37.5 n = 6 Health Status: unhealthy Condition: Asthma Age Group: 37.5 Sex: M+F Population Size: 6 Sources: Page: p.1465 |
|
200 mg single, intrabursal Overdose Dose: 200 mg Route: intrabursal Route: single Dose: 200 mg Sources: Page: p.13 |
unhealthy, 46 n = 1 Health Status: unhealthy Condition: Bursitis Age Group: 46 Sex: F Population Size: 1 Sources: Page: p.13 |
Disc. AE: Cushing's syndrome... AEs leading to discontinuation/dose reduction: Cushing's syndrome Sources: Page: p.13 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Cushing's syndrome | Disc. AE | 200 mg single, intrabursal Overdose Dose: 200 mg Route: intrabursal Route: single Dose: 200 mg Sources: Page: p.13 |
unhealthy, 46 n = 1 Health Status: unhealthy Condition: Bursitis Age Group: 46 Sex: F Population Size: 1 Sources: Page: p.13 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/10570047/ |
weak |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes | likely (co-administration study) Comment: Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects. Co-administration of other strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin, cobicistat-containing products) with Kenalog-10 Injection may cause increased plasma concentration of triamcinolone leading to adverse reactions. Page: 10.0 |
PubMed
Title | Date | PubMed |
---|---|---|
Functional probing of the human glucocorticoid receptor steroid-interacting surface by site-directed mutagenesis. Gln-642 plays an important role in steroid recognition and binding. | 2000 Jun 23 |
|
[Experiences with liposuction of established surgeons]. | 2001 |
|
Cutaneous drug reaction case reports: from the world literature. | 2001 |
|
Clinical prescribing of allergic rhinitis medication in the preschool and young school-age child: what are the options? | 2001 |
|
[Oral lichen planus. 2. Therapy possibilities and current treatment concepts]. | 2001 |
|
Choroidal granulomas in systemic sarcoidosis. | 2001 |
|
Transforming growth factor beta2 induced pleurodesis is not inhibited by corticosteroids. | 2001 Aug |
|
Symptomatic lumbar synovial cyst: management with direct CT-guided puncture and steroid injection. | 2001 Dec |
|
Intralesional corticosteroid injection for treatment of central giant-cell granuloma. | 2001 Feb |
|
Isolated tuberculous monoarthritis mimicking oligoarticular juvenile rheumatoid arthritis. | 2001 Jan |
|
Triamcinolone: new and old indications. | 2001 Jul |
|
Necrobiosis lipoidica in a 9-year-old girl with new-onset type II diabetes mellitus. | 2001 Jul-Aug |
|
A minimally invasive approach for treating postoperative seromas after incisional hernia repair. | 2001 Jul-Sep |
|
Effects of triamcinolone acetonide on microglial morphology and quantitative expression of MHC-II in exudative age-related macular degeneration. | 2001 Jun |
|
Lesson of the week: Depot corticosteroid treatment for hay fever causing avascular necrosis of both hips. | 2001 Jun 30 |
|
Investigation of some commercially available spacer devices for the delivery of glucocorticoid steroids from a pMDI. | 2001 May |
|
High injection pressure during intralesional injection of corticosteroids into capillary hemangiomas. | 2001 May |
|
Tumescent steroid infiltration to reduce postoperative swelling after craniofacial surgery. | 2001 Oct |
|
Two cases of morphea associated with Hashimoto's thyroiditis. | 2002 |
|
Topical steroid therapy for phimosis. | 2002 Apr |
|
Intralesional triamcinolone for chondrodermatitis nodularis: a follow-up study of 60 patients. | 2002 Apr |
|
[The effect of triamcinolone acetonide, montelukast, nedocromil sodium, formoterol on levels levels of sICAM-1, sIL-2R in serum and clinical course of asthma in children]. | 2002 Feb |
|
A randomized, double-blind trial of the effect of glucocorticoid, antileukotriene and beta-agonist treatment on IL-10 serum levels in children with asthma. | 2002 Feb |
|
Shoulder joint capsule distension (hydroplasty): a case series of patients with "frozen shoulders" treated in a primary care office. | 2002 Jan |
|
Macrophage migration inhibitory factor in patients with juvenile idiopathic arthritis. | 2002 Jan |
|
Stopping triamcinolone led to treatment failures in patients with persistent asthma who were receiving salmeterol and triamcinolone. | 2002 Jan-Feb |
|
Salmeterol was not as effective as triamcinolone for persistent asthma. | 2002 Jan-Feb |
|
Intravitreal triamcinolone in recurrence of choroidal neovascularisation. | 2002 Jun |
|
Spontaneous bleeding following steroid injection and silicone-gel sheeting in a keloid scar. | 2002 Mar |
|
CD30-positive T-cell-rich pseudolymphoma induced by gold acupuncture. | 2002 May |
|
Laser-induced weal and flare reactions: clinical aspects and pharmacological modulation. | 2002 May |
|
Intravitreal triamcinolone for refractory diabetic macular edema. | 2002 May |
|
Intravitreal triamcinolone in subfoveal recurrence of choroidal neovascularisation after laser treatment in macular degeneration. | 2002 May |
|
Local injection treatment for lateral epicondylitis. | 2002 May |
|
A glucocorticoid-responsive mutant androgen receptor exhibits unique ligand specificity: therapeutic implications for androgen-independent prostate cancer. | 2002 May |
|
Systemic effect comparisons of six inhaled corticosteroid preparations. | 2002 May 15 |
Sample Use Guides
The initial intramuscular dosage of triamcinolone diacetate injectable suspension may vary from 3 to 48 mg per day depending on the specific disease entity being treated
Route of Administration:
Intramuscular
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14406639
Unknown
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:03:26 GMT 2023
by
admin
on
Fri Dec 15 16:03:26 GMT 2023
|
Record UNII |
A73MM2Q32P
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C521
Created by
admin on Fri Dec 15 16:03:26 GMT 2023 , Edited by admin on Fri Dec 15 16:03:26 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C030262
Created by
admin on Fri Dec 15 16:03:26 GMT 2023 , Edited by admin on Fri Dec 15 16:03:26 GMT 2023
|
PRIMARY | |||
|
100000084641
Created by
admin on Fri Dec 15 16:03:26 GMT 2023 , Edited by admin on Fri Dec 15 16:03:26 GMT 2023
|
PRIMARY | |||
|
6216
Created by
admin on Fri Dec 15 16:03:26 GMT 2023 , Edited by admin on Fri Dec 15 16:03:26 GMT 2023
|
PRIMARY | |||
|
2727
Created by
admin on Fri Dec 15 16:03:26 GMT 2023 , Edited by admin on Fri Dec 15 16:03:26 GMT 2023
|
PRIMARY | |||
|
DBSALT000859
Created by
admin on Fri Dec 15 16:03:26 GMT 2023 , Edited by admin on Fri Dec 15 16:03:26 GMT 2023
|
PRIMARY | |||
|
m11027
Created by
admin on Fri Dec 15 16:03:26 GMT 2023 , Edited by admin on Fri Dec 15 16:03:26 GMT 2023
|
PRIMARY | Merck Index | ||
|
A73MM2Q32P
Created by
admin on Fri Dec 15 16:03:26 GMT 2023 , Edited by admin on Fri Dec 15 16:03:26 GMT 2023
|
PRIMARY | |||
|
Triamcinolone diacetate
Created by
admin on Fri Dec 15 16:03:26 GMT 2023 , Edited by admin on Fri Dec 15 16:03:26 GMT 2023
|
PRIMARY | |||
|
10762
Created by
admin on Fri Dec 15 16:03:26 GMT 2023 , Edited by admin on Fri Dec 15 16:03:26 GMT 2023
|
PRIMARY | RxNorm | ||
|
CHEMBL1200449
Created by
admin on Fri Dec 15 16:03:26 GMT 2023 , Edited by admin on Fri Dec 15 16:03:26 GMT 2023
|
PRIMARY | |||
|
1678005
Created by
admin on Fri Dec 15 16:03:26 GMT 2023 , Edited by admin on Fri Dec 15 16:03:26 GMT 2023
|
PRIMARY | |||
|
C61985
Created by
admin on Fri Dec 15 16:03:26 GMT 2023 , Edited by admin on Fri Dec 15 16:03:26 GMT 2023
|
PRIMARY | |||
|
67-78-7
Created by
admin on Fri Dec 15 16:03:26 GMT 2023 , Edited by admin on Fri Dec 15 16:03:26 GMT 2023
|
PRIMARY | |||
|
200-669-0
Created by
admin on Fri Dec 15 16:03:26 GMT 2023 , Edited by admin on Fri Dec 15 16:03:26 GMT 2023
|
PRIMARY | |||
|
SUB04938MIG
Created by
admin on Fri Dec 15 16:03:26 GMT 2023 , Edited by admin on Fri Dec 15 16:03:26 GMT 2023
|
PRIMARY | |||
|
DTXSID0048713
Created by
admin on Fri Dec 15 16:03:26 GMT 2023 , Edited by admin on Fri Dec 15 16:03:26 GMT 2023
|
PRIMARY | |||
|
757356
Created by
admin on Fri Dec 15 16:03:26 GMT 2023 , Edited by admin on Fri Dec 15 16:03:26 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |